D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $5.00 price objective on the stock.

A number of other equities analysts have also weighed in on VNRX. Maxim Group lowered VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday. HC Wainwright decreased their price objective on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $3.17.

VolitionRx Trading Down 3.8%

Shares of VNRX opened at $0.30 on Thursday. The company has a market cap of $36.80 million, a price-to-earnings ratio of -0.83 and a beta of 1.26. The business’s fifty day simple moving average is $0.43 and its two-hundred day simple moving average is $0.58. VolitionRx has a 12 month low of $0.27 and a 12 month high of $0.94.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes bought 96,153 shares of the business’s stock in a transaction that occurred on Tuesday, October 14th. The stock was bought at an average cost of $0.51 per share, for a total transaction of $49,038.03. Following the completion of the transaction, the director owned 1,062,967 shares of the company’s stock, valued at $542,113.17. This represents a 9.95% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds bought 110,000 shares of VolitionRx stock in a transaction on Tuesday, October 14th. The shares were acquired at an average cost of $0.51 per share, with a total value of $56,100.00. Following the completion of the acquisition, the chief executive officer owned 2,534,847 shares of the company’s stock, valued at $1,292,771.97. The trade was a 4.54% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 289,229 shares of company stock worth $146,557. 10.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On VolitionRx

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Silverberg Bernstein Capital Management LLC grew its holdings in VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Blair William & Co. IL purchased a new position in shares of VolitionRx during the 2nd quarter valued at about $30,000. Armistice Capital LLC grew its stake in shares of VolitionRx by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares during the period. Lagoda Investment Management L.P. increased its holdings in VolitionRx by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock worth $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in VolitionRx by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.